ORIGINAL ARTICLE

Clinical manifestations and outcomes of coronavirus disease-19 in heart transplant recipients: a multicentre case series with a systematic review and meta-analysis

Camille Granger¹*, Paul Guedeney¹* (D), Camille Arnaud², Soulef Guendouz³, Claire Cimadevilla², Mathieu Kerneis¹, Caroline Kerneis², Michel Zeitouni¹, Constance Verdonk², Camille Legeai⁴ (D), Guillaume Lebreton⁵, Pascal Leprince⁵, Eva Désiré⁵, Sabato Sorrentino⁶, Johanne Silvain¹, Gilles Montalescot¹, Fanny Hazan⁵, Shaida Varnous⁵ & Richard Dorent^{2,4}

 ACTION Study Group, INSERM UMRS_1166, Institut de Cardiologie, Pitié Salpêtrière, Assistance
 Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France
 Département de Chirurgie
 Cardiaque, Hôpital Bichat, Assistance Publique-Hôpitaux de
 Paris, Université de Paris, Paris, France

3 Département de Cardiologie, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France

4 Agence de la Biomédecine, Direction Prélèvement Greffe Organes-Tissus, Saint Denis La Plaine, France

5 Département de Chirurgie Cardiaque, Institut de Cardiologie, Pitié Salpêtrière Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France

6 Division of Cardiology, Department of Medical and Surgical Sciences, URT National Research Council (CNR), Magna Graecia University, Catanzaro, Italy

Correspondence

Dr. Richard Dorent, MD, Agence de la Biomédecine, Direction Prélèvement Greffe Organes-Tissus, 1 avenue du Stade de France, 93212 Saint-Denis La Plaine cedex, France. Tel.: +33 1 55 93 64 65; fax: +33 1 55 93 69 30;

SUMMARY

Available data on clinical presentation and mortality of coronavirus disease-2019 (COVID-19) in heart transplant (HT) recipients remain limited. We report a case series of laboratory-confirmed COVID-19 in 39 HT recipients from 3 French heart transplant centres (mean age 54.4 ± 14.8 years; 66.7% males). Hospital admission was required for 35 (89.7%) cases including 14/39 (35.9%) cases being admitted in intensive care unit. Immunosuppressive medications were reduced or discontinued in 74.4% of the patients. After a median follow-up of 54 (19-80) days, death and death or need for mechanical ventilation occurred in 25.6% and 33.3% of patients, respectively. Elevated C-reactive protein and lung involvement >50% on chest computed tomography (CT) at admission were associated with an increased risk of death or need for mechanical ventilation. Mortality rate from March to June in the entire 3-centre HT recipient cohort was 56% higher in 2020 compared to the time-matched 2019 cohort (2% vs. 1.28%, P = 0.15). In a meta-analysis including 4 studies, pre-existing diabetes mellitus (OR 3.60, 95% CI 1.43–9.06, $I^2 = 0\%$, P = 0.006) and chronic kidney disease stage III or higher (OR 3.79, 95%) CI 1.39–10.31, $I^2 = 0\%$, P = 0.009) were associated with increased mortality. These findings highlight the aggressive clinical course of COVID-19 in HT recipients.

Transplant International 2021; 34: 721–731

Key words

COVID-19, heart transplant, immunosuppressive medication

Received: 13 September 2020; Revision requested: 14 October 2020; Accepted: 29 January 2021; Published online: 5 March 2021

e-mail: richard.dorent@biomedecine.fr

*Both authors equally contributed to the manuscript.

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) emerged in December 2019 in Wuhan, China, and has been spreading worldwide ever since into a global pandemic. As of the end of October 2020, nearly 50 million people were infected, worldwide, with approximately 1.2 million deaths [1]. COVID-19 has a wide clinical spectrum, ranging from asymptomatic infection to mild upper respiratory tract illness, acute respiratory distress syndrome and acute cardiac injury [2-5]. Although the risk of viral infection is markedly increased among solid organ transplant recipients, including heart transplant (HT) recipients, available data on clinical presentation and outcomes of COVID-19 in this high-risk population remain limited [6-12]. In addition to chronic immunosuppression-related risk, HT recipients commonly present with cardiovascular disease and cardiovascular risk factors, which have been associated with more frequent COVID-19 infection and with worse outcomes [13-15]. The purpose of our study was to describe the clinical characteristics, outcomes and treatment management of laboratory-confirmed COVID-19 HT recipients from 3 heart transplant centres located in Ile-de-France area, the most populated region in France with 12.2 million inhabitants and ranking first in total number of COVID-19 cases. To evaluate the relative increase in mortality in HT recipients during COVID-19, we compared the mortality rate in the entire HT recipient cohorts of the three centres from March to June 2019 to the one from March to June 2020. Furthermore, we performed a systematic review and meta-analysis of published studies reporting COVID-19 outcomes in HT recipients to identify factors associated with death.

Methods

Study population

We performed a prospective case series study according to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines (Table S1). All adult HT recipients (≥18 years old) from 3 heart transplant centres located in Ile-de-France (Pitié Salpêtrière Hospital, Henri Mondor Hospital and Bichat-Claude Bernard Hospital) with laboratory-confirmed COVID-19 infection from 6 March to 29 June 2020 were included. Such patients have long been instructed to actively consult or report to their respective centre in case of acute dyspnoea or new onset of fever. Furthermore, with the beginning of the pandemic in France, a systematic review of COVID-19 infection was prospectively performed in each centre. Diagnosis of SARS-CoV-2 infection was performed either by reverse transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal swabs or through serology testing. Data collection included baseline characteristics, clinical presentation and radiologic findings in all patients as well as laboratory data in hospitalized patients. Follow-up was performed through clinical evaluation or by phone interview. Management of immunosuppressive therapy was left at the discretion of local transplant physicians, in accordance with local practice and the practical guide of the French Society of Transplantation published early April 2020 (Table S2).

Outcomes

The end point of interest was the occurrence of death or mechanical ventilation. Risk factors for these adverse outcomes were determined from baseline characteristics and initial presentation. Furthermore, the relative increase in mortality during the SARS-CoV-2 pandemic was assessed in the entire cohort of HT recipients followed in the three centres by comparing the mortality rates from March to June 2020 and from March to June 2019. The mortality rates among the entire HT recipients cohort of the three centres during the time periods of interest were provided by the Agence de Biomedecine, a governmental agency that prospectively collects data on all transplant recipients in France along with their outcomes.

Meta-analysis of observational studies

To further improve the description of the mortality and morbidity associated with COVID-19 in HT recipients, we performed a systematic review through PubMed and Embase databases of observational studies reporting outcomes following COVID-19 in HT recipients. The estimate of incidence of death was provided by pooling study-level data of all the studies as one population. We performed a meta-analysis including the studies comprising of at least 10 patients and providing clinical description of fatalities cases following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) guidelines to determine potential risk factors for death in COVID-19 HT recipients (Table S3). A full electronic search was conducted in PUBMED and Embase, and the terms used for research were "COVID-19", "SARS-CoV-2", "Heart transplant recipient", "solid organ recipient", up to December 2020. Citations were screened at the title and the abstract level and retrieved if considered relevant. The main inclusion criterion was an observational study reporting baseline characteristics and clinical outcomes in HT recipients with confirmed COVID-19, without any restriction on follow-up. Single case reports and small case series (n < 10 patients) were excluded from the meta-analysis. End point of interest was death from any cause. Data were extracted using a standardized form by two investigators (C.G. and P.G.), and discrepancies were resolved by consensus. The following relevant data were collected: first author, year of publication, total sample size, baseline characteristics such as age, time from transplantation, diabetes mellitus, hypertension, cardiac allograft vasculopathy (CAV), chronic kidney disease, immunosuppressive treatments, need for hospitalization and death.

Statistics

Categorical variables were described as number (%), and continuous variables were described with mean \pm standard deviation or median (IQR), as appropriate. Categorical variables were compared using the Fisher's exact test or chi-square test, and continuous variables were compared using Student's t-test. Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. With the increased statistical power provided by the meta-analysis, we evaluated potential risk factors for mortality following COVID-19 in HT recipient. Odds ratio (OR) and 95% confidence interval [CI] were determined using Mantel-Haenszel fixed-effect models according to DerSimonian and Laird. Heterogeneity among trials for each outcome was estimated with chi-square tests and quantified with I^2 statistics (with $I^2 < 50\%$, 50–75% and >75% indicating low, moderate and high heterogeneity, respectively). Publication bias was estimated via visual inspection of the funnel plot of the effect

estimates of variables tested in the meta-analysis from the four studies against study size and precision.

Analyses were conducted using GRAPHPAD PRISM v8.4.3 (GraphPad Software, Inc, San Diego, CA, USA) and the Cochrane's Review Manager (RevMan) version 5.4 (The Cochrane Collaboration, Copenhagen, Denmark).

Results

Clinical presentation, diagnosis and management

A total of 39 HT recipients were included, with confirmed SARS-CoV-2 infection with RT-PCR in 37/39 (94.9%) cases. COVID-19 was confirmed with serology in 2/39 (5.1%) cases, including one patient presenting with repeated negative RT-PCR tests despite clinical and radiological profile highly suggestive with COVID-19 and another patient, asymptomatic but exposed to the disease. Among COVID-19 cases confirmed with RT-PCR, several tests were performed on 19/37 (51.3%) patients, with a median of 2 (2-3.3) tests per patient and 15.5 [5-27] days between the first and last PCR test (Fig. S1). Patient demographics, primary diagnosis, comorbidities and therapies are detailed in Table 1. The most frequently encountered clinical presentation were respiratory tract symptoms together with fever and dyspnoea (Table 2). A chest CT imaging was performed in 33/39 (84.6%) patients, without any case of reported pulmonary embolism. A total of 35/39 (89.7%) patients were hospitalized, including 14/39 (35.9%) patients in intensive care unit, while 4/39 (10.3%) were managed as outpatients. Median duration of hospitalization was 14 (8.5-27.5) days. Oxygen supplementation was required in 18 patients. Reduction of patients' baseline immunosuppressive therapy was performed in 29/39 (74.4%) cases. Conversely, corticosteroid therapy was maintained. A total of 21/39 (53.8%) patients were managed with antibiotics, while 6/39 (15.4%) and 1/39 (2.6%) received hydroxychologuine and lopinavir-ritonavir, respectively. There was no use of remdesivir or convalescent plasma in the cohort.

Cardiac manifestations

There was no reported case of new onset of cardiac arrythmia among hospitalized patients. Of the 32 patients with whom cardiac troponin was measured, a total of 23 presented with some degree of myocardial injury, with a troponin peak above the 99th percentile. Cardiac echocardiography was performed in 16 patients and reported a new onset of moderate alteration of left

Table II Fatient characteristics.	
Age, years	54.4 ± 14.8
Male sex	26/39 (66.7%)
Underlying cardiomyopathy	Ischaemic
prior to transplant	cardiomyopathy: 11/39
	(28.2%)
	Dilated
	cardiomyopathy: 18/39
	(46.2%)
	Hypertrophic
	cardiomyopathy: 4/39
	(10.2%)
	Valvular cardiomyopathy:
	3/39 (7.7%)
	Other: 3/39 (7.7%)
Blood type	O: 15/39 (38.5%)
	A: 15/39 (38.5%)
	B: 8/39 (20.5%)
	AB: 1/39 (2.5%)
Time from transplantation, years	4.9 (1.8–7.7)
Prior acute rejection	25/39 (64.1%)
ISHLT cardiac allograft	9/39 (23.1%)
vasculopathy 2 or 3	
Serology status	/
CMV-positive	26/38 (68.4%)
EBV-positive	35/37 (94.6%)
Baseline echocardiographic evaluat	
LV ejection fraction, %	64.0 (60.0–68.0)
LV end-diastolic diameter, mm	48.0 (44–51.0)
Kidney function	
Creatinine, µmol/l	126 (98.0–163.5)
Chronic kidney disease	21/39 (53.8%)
stage III or higher	
On dialysis	6/39 (15.4%)
Prior cardiac arrhythmia	4/39 (10.3%)
Inflammatory disease	5/39 (12.8%)
Prior stroke or transient ischaemic attack	6/39 (15.4%)
	2/20 /F 10/)
Peripheral vascular disease	2/39 (5.1%) 2/39 (5.1%)
Active smoking	
Diabetes mellitus	16/39 (40.0%)
Dyslipidaemia	12/39 (30.8%)
Hypertension Family history of	28/39 (71.8%)
cardiovascular disease	4/39 (10.3%)
-	27.0 ± 5.5
Body mass index, kg/m ² Baseline medication	27.0 ± 5.5
	30/30 (76 0 5%)
Single antiplatelet therapy	30/39 (76.9.5%) 5/39 (12.8%)
Dual antiplatelet therapy	5/39 (12.8%)
Statin Bata blocker	30/39 (76.9%) 26/20 (66 7%)
Beta-blocker	26/39 (66.7%)
ACE-I or ARBs	16/39 (41.0%)
MRA Oral anticoagulant	1/39 (2.6%)
Oral anticoagulant	3/39 (7.7%)
Insulin Oral antidiabatic agent	10/39 (25.6%)
Oral antidiabetic agent	3/39 (7.7%)

37/39 (94.9%)

Table 1. Patient characteristics.

7/37 (18.9%)
28/39 (71.8%)
16/39 (41.0%)
22/39 (56.4%)
11/39 (28.2%)
4/39 (10.3%)

ACE-I, angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; CMV, cytomegalovirus; EBV, Epstein Barr virus; LV, left ventricular; ISHLT: International Society for Heart and Lung Transplantation; MRA: mineralocorticoid receptor antagonist.

Variables are provided as mean \pm standard deviation or median (IQR).

ventricle ejection fraction (i.e. 40-45%) in three cases, all of whom were later treated with mechanical ventilation and two of whom eventually died.

Outcomes

The median duration of follow-up was 54 (19-80) days during which death and death or need for mechanical ventilation occurred in 10/39 (25.6%) and 13/39 (33.3%) patients, respectively. C-reactive protein at admission and lung involvement ≥50% on chest CT were associated with occurrence of death or need for mechanical ventilation (Table 3). There were 17/39 (43.6%) cases of acute kidney injury and 6/39 (15.4%) patients required new onset of renal replacement therapy.

Among the 1248 HT recipients followed in the three participating centres on March 2019, 16 (1.28%) died by June 2019 whereas 26 of 1299 (2%) died from March to June 2020, although this 56% relative increase in mortality in 2020 was not statistically significant (P = 0.15). The 3-month survival was 99% in 2019 compared to 98.1% in 2020 (P = 0.15; Fig. 1).

Meta-analysis

We screened 41 published studies [9,11,12,16–53] (Fig. S2 and Table S2) evaluating outcomes HT recipients with confirmed SARS-CoV-2 infection. When including the present case series, the overall reported proportion of death was 88/398 (22.1%; 95% confidence interval [CI] 18.3-26.4%). Overall, four studies, counting the present case series, were included in the metaanalysis, comprising of 120 patients [18,47,52]. Factors associated with death were pre-existing diabetes mellitus

Prednisone

Between 10% and 50% 8/33 (24.2%) ≥50% 11/33 (33.3%) Admission for COVID-19 34/39 (87.2%) Admission in intensive care unit 14/39 (35.9%) Delay between symptom 5.0 (2.0–10.0) onset and hospital admission, days 29/39 (74.4%) Covid-related modification 29/39 (74.4%) of immunosuppressive therapy Transient withdrawal or reduction of 4/17 (23.5%) Mycophenolate mofetil 22/29 (76%) Tacrolimus 4/17 (23.5%) Cyclosporine 1/22 (4.5%) Everolimus 4/11 (36%) Azathioprine 2/4 (50%) Biological characteristics Creatinine, µmol/l (n = 38) On admission 150.5 (107.3–307.8) Peak 221.5 (108.8–438.8) NT-proBNP, ng/l 955.0 (320.0–4079) Deak (n = 29) 2257.0 (638.0–7620.0) White blood cells count, 10 ⁹ /l (n = 36) 0n admission On admission 5.8 (4.2–8.4) Peak 8.9 (5.7–13.3) Lymphocyte count, 10 ⁹ /l (n = 36) 0n admission (n = 37) On admission 0.65 (0.40–0.91)	<u>≤</u> 10%	14/33 (42.4%)	
Admission for COVID-19 $34/39 (87.2\%)$ Admission in intensive care unit $14/39 (35.9\%)$ Delay between symptom $5.0 (2.0-10.0)$ onset and hospital admission, days $29/39 (74.4\%)$ Covid-related modification $29/39 (74.4\%)$ of immunosuppressive therapy $7ransient withdrawal or$ reduction of $22/29 (76\%)$ Mycophenolate mofetil $22/29 (76\%)$ Tacrolimus $4/17 (23.5\%)$ Cyclosporine $1/22 (4.5\%)$ Everolimus $4/11 (36\%)$ Azathioprine $2/4 (50\%)$ Biological characteristics $Creatinine, \mumol/l (n = 38)$ On admission $150.5 (107.3-307.8)$ Peak $221.5 (108.8-438.8)$ NT-proBNP, ng/l $955.0 (320.0-4079)$ Peak (n = 29) $2257.0 (638.0-7620.0)$ White blood cells count, $10^9/l (n = 36)$ $0n$ admissionOn admission $5.8 (4.2-8.4)$ Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/l (n = 36)$ $0n$ admission (n = 37)On admission (n = 37) 11.6 ± 2.0 Nadir (n = 24) 9.4 ± 2.6 C-Reactive protein, mg/l (n = 36) $0n$ admissionOn admission $43.8 (20.2-87.3)$ Peak $10.2 (34.8-217.8)$ Procalcitonin, $\mu g/l (n = 27)$ $0.48 (0.08-0.86)$	Between 10% and 50%	8/33 (24.2%)	
Admission in intensive care unit $14/39 (35.9\%)$ Delay between symptom $5.0 (2.0-10.0)$ onset and hospital admission, daysCovid-related modification $29/39 (74.4\%)$ of immunosuppressive therapyTransient withdrawal orreduction ofMycophenolate mofetil $22/29 (76\%)$ Tacrolimus $4/17 (23.5\%)$ Cyclosporine $1/22 (4.5\%)$ Everolimus $4/11 (36\%)$ Azathioprine $2/4 (50\%)$ Biological characteristicsCreatinine, μ mol/l ($n = 38$)On admission $150.5 (107.3-307.8)$ Peak $221.5 (108.8-438.8)$ NT-proBNP, ng/lOn admission ($n = 26$) $955.0 (320.0-4079)$ Peak ($n = 29$) $2257.0 (638.0-7620.0)$ White blood cells count, $10^9/l (n = 36)$ On admission $5.8 (4.2-8.4)$ Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/l (n = 36)$ On admission ($n = 37$) 11.6 ± 2.0 Nadir $0.48 (0.28-0.72)$ Haemoglobin, g/dlOn admission ($n = 37$) 11.6 ± 2.0 Nadir ($n = 24$) 9.4 ± 2.6 C-Reactive protein, mg/l ($n = 36$)On admission $43.8 (20.2-87.3)$ Peak $100.2 (34.8-217.8)$ Procalcitonin, $\mu g/l (n = 27)$ $0.48 (0.08-0.86)$	≥50%	11/33 (33.3%)	
Delay between symptom5.0 (2.0–10.0)onset and hospital admission, daysCovid-related modification29/39 (74.4%)of immunosuppressive therapyTransient withdrawal orreduction ofMycophenolate mofetil22/29 (76%)Tacrolimus4/17 (23.5%)Cyclosporine1/22 (4.5%)Everolimus4/11 (36%)Azathioprine2/4 (50%)Biological characteristicsCreatinine, μ mol/l ($n = 38$)On admission150.5 (107.3–307.8)Peak221.5 (108.8–438.8)NT-proBNP, ng/lOn admission ($n = 26$)955.0 (320.0–4079)Peak ($n = 29$)2257.0 (638.0–7620.0)White blood cells count, $10^9/l$ ($n = 36$)On admission5.8 (4.2–8.4)Peak8.9 (5.7–13.3)Lymphocyte count, $10^9/l$ ($n = 36$)On admission ($n = 37$)11.6 \pm 2.0Nadir0.48 (0.28–0.72)Haemoglobin, g/dl0.48 (0.28–0.72)On admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, $\mu g/l$ ($n = 27$)0.48 (0.08–0.86)	Admission for COVID-19	34/39 (87.2%)	
onset and hospital admission, days Covid-related modification 29/39 (74.4%) of immunosuppressive therapy Transient withdrawal or reduction of Mycophenolate mofetil 22/29 (76%) Tacrolimus 4/17 (23.5%) Cyclosporine 1/22 (4.5%) Everolimus 4/11 (36%) Azathioprine 2/4 (50%) Biological characteristics Creatinine, μ mol/l ($n = 38$) On admission 150.5 (107.3–307.8) Peak 221.5 (108.8–438.8) NT-proBNP, ng/l On admission ($n = 26$) 955.0 (320.0–4079) Peak ($n = 29$) 2257.0 (638.0–7620.0) White blood cells count, 10 ⁹ /l ($n = 36$) On admission 5.8 (4.2–8.4) Peak 8.9 (5.7–13.3) Lymphocyte count, 10 ⁹ /l ($n = 36$) On admission 0.65 (0.40–0.91) Nadir 0.48 (0.28–0.72) Haemoglobin, g/dl On admission ($n = 37$) 11.6 ± 2.0 Nadir ($n = 24$) 9.4 ± 2.6 C-Reactive protein, mg/l ($n = 36$) On admission 43.8 (20.2–87.3) Peak 100.2 (34.8–217.8) Procalcitonin, μ g/l ($n = 27$) On admission 0.48 (0.08–0.86)	Admission in intensive care unit	14/39 (35.9%)	
Covid-related modification $29/39 (74.4\%)$ of immunosuppressive therapyTransient withdrawal orreduction ofMycophenolate mofetil $22/29 (76\%)$ Tacrolimus $4/17 (23.5\%)$ Cyclosporine $1/22 (4.5\%)$ Everolimus $4/11 (36\%)$ Azathioprine $2/4 (50\%)$ Biological characteristicsCreatinine, μ mol/l ($n = 38$)On admission $150.5 (107.3-307.8)$ Peak $221.5 (108.8-438.8)$ NT-proBNP, ng/lOn admission ($n = 26$) $955.0 (320.0-4079)$ Peak ($n = 29$) $2257.0 (638.0-7620.0)$ White blood cells count, $10^9/l (n = 36)$ On admission $5.8 (4.2-8.4)$ Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/l (n = 36)$ On admission $0.65 (0.40-0.91)$ Nadir $0.48 (0.28-0.72)$ Haemoglobin, g/dlOn admission ($n = 37$)I1.6 ± 2.0 Nadir ($n = 24$) 9.4 ± 2.6 C-Reactive protein, mg/l ($n = 36$)On admission $43.8 (20.2-87.3)$ Peak $100.2 (34.8-217.8)$ Procalcitonin, $\mu g/l (n = 27)$ On admission $0.48 (0.08-0.86)$	Delay between symptom	5.0 (2.0–10.0)	
of immunosuppressive therapy Transient withdrawal or reduction of Mycophenolate mofetil 22/29 (76%) Tacrolimus 4/17 (23.5%) Cyclosporine 1/22 (4.5%) Everolimus 4/11 (36%) Azathioprine 2/4 (50%) Biological characteristics Creatinine, μ mol/1 ($n = 38$) On admission 150.5 (107.3–307.8) Peak 221.5 (108.8–438.8) NT-proBNP, ng/1 On admission ($n = 26$) 955.0 (320.0–4079) Peak ($n = 29$) 2257.0 (638.0–7620.0) White blood cells count, 10 ⁹ /1 ($n = 36$) On admission 5.8 (4.2–8.4) Peak 8.9 (5.7–13.3) Lymphocyte count, 10 ⁹ /1 ($n = 36$) On admission 0.65 (0.40–0.91) Nadir 0.48 (0.28–0.72) Haemoglobin, g/dl On admission 43.8 (20.2–87.3) Peak 100.2 (34.8–217.8) Procalcitonin, μ g/1 ($n = 27$) On admission 0.48 (0.08–0.86)	onset and hospital admission, days		
Transient withdrawal or reduction of22/29 (76%)Mycophenolate mofetil22/29 (76%)Tacrolimus4/17 (23.5%)Cyclosporine1/22 (4.5%)Everolimus4/11 (36%)Azathioprine2/4 (50%)Biological characteristicsCreatinine, μ mol/l ($n = 38$)On admission150.5 (107.3–307.8)Peak221.5 (108.8–438.8)NT-proBNP, ng/lOn admission ($n = 26$)955.0 (320.0–4079)Peak ($n = 29$)2257.0 (638.0–7620.0)White blood cells count, 10^9 /l ($n = 36$)On admission5.8 (4.2–8.4)Peak8.9 (5.7–13.3)Lymphocyte count, 10^9 /l ($n = 36$)On admission ($n = 37$)11.6 ± 2.0Nadir0.48 (0.28–0.72)Haemoglobin, g/dl0.65On admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, μ g/l ($n = 27$)0.48 (0.08–0.86)	Covid-related modification	29/39 (74.4%)	
reduction ofMycophenolate mofetil22/29 (76%)Tacrolimus4/17 (23.5%)Cyclosporine1/22 (4.5%)Everolimus4/11 (36%)Azathioprine2/4 (50%)Biological characteristicsCreatinine, μ mol/l ($n = 38$)On admission150.5 (107.3–307.8)Peak221.5 (108.8–438.8)NT-proBNP, ng/lOn admission ($n = 26$)955.0 (320.0–4079)Peak ($n = 29$)2257.0 (638.0–7620.0)White blood cells count, 10^9 /l ($n = 36$)On admission5.8 (4.2–8.4)Peak8.9 (5.7–13.3)Lymphocyte count, 10^9 /l ($n = 36$)On admission ($n = 37$)11.6 ± 2.0Nadir0.48 (0.28–0.72)Haemoglobin, g/dl0.65 (0.40–0.91)Nadir ($n = 24$)9.4 ± 2.6C-Reactive protein, mg/l ($n = 36$)On admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, μ g/l ($n = 27$)On admission0.48 (0.08–0.86)	of immunosuppressive therapy		
Mycophenolate mofetil $22/29 (76\%)$ Tacrolimus $4/17 (23.5\%)$ Cyclosporine $1/22 (4.5\%)$ Everolimus $4/11 (36\%)$ Azathioprine $2/4 (50\%)$ Biological characteristicsCreatinine, μ mol/l ($n = 38$)On admission $150.5 (107.3-307.8)$ Peak $221.5 (108.8-438.8)$ NT-proBNP, ng/l $0n$ admission ($n = 26$)On admission ($n = 26$) $955.0 (320.0-4079)$ Peak ($n = 29$) $2257.0 (638.0-7620.0)$ White blood cells count, $10^9/l (n = 36)$ $0n$ admissionOn admission $5.8 (4.2-8.4)$ Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/l (n = 36)$ $0n$ admission ($n = 37$)On admission ($n = 37$) 11.6 ± 2.0 Nadir ($n = 24$) 9.4 ± 2.6 C-Reactive protein, mg/l ($n = 36$) $0n$ admissionOn admission $43.8 (20.2-87.3)$ Peak $100.2 (34.8-217.8)$ Procalcitonin, $\mu g/l (n = 27)$ $0.48 (0.08-0.86)$	Transient withdrawal or		
Tarolimus $4/17 (23.5\%)$ Cyclosporine $1/22 (4.5\%)$ Everolimus $4/11 (36\%)$ Azathioprine $2/4 (50\%)$ Biological characteristics $Creatinine, \mu mol/l (n = 38)$ On admission $150.5 (107.3-307.8)$ Peak $221.5 (108.8-438.8)$ NT-proBNP, ng/l $955.0 (320.0-4079)$ Peak (n = 29) $2257.0 (638.0-7620.0)$ White blood cells count, $10^9/l (n = 36)$ $0n$ admissionOn admission $5.8 (4.2-8.4)$ Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/l (n = 36)$ $0n$ admissionOn admission $0.65 (0.40-0.91)$ Nadir $0.48 (0.28-0.72)$ Haemoglobin, g/dl $0n$ admission (n = 37)On admission 9.4 ± 2.6 C-Reactive protein, mg/l (n = 36) $0n$ admissionOn admission $43.8 (20.2-87.3)$ Peak $100.2 (34.8-217.8)$ Procalcitonin, $\mu g/l (n = 27)$ $0.48 (0.08-0.86)$	reduction of		
Cyclosporine $1/22 (4.5\%)$ Everolimus $4/11 (36\%)$ Azathioprine $2/4 (50\%)$ Biological characteristicsCreatinine, µmol/l ($n = 38$)On admission $150.5 (107.3-307.8)$ Peak $221.5 (108.8-438.8)$ NT-proBNP, ng/lOn admission ($n = 26$) $955.0 (320.0-4079)$ Peak ($n = 29$) $2257.0 (638.0-7620.0)$ White blood cells count, $10^9/l (n = 36)$ On admission $5.8 (4.2-8.4)$ Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/l (n = 36)$ On admission $0.65 (0.40-0.91)$ Nadir $0.48 (0.28-0.72)$ Haemoglobin, g/dlOn admission ($n = 37$)Nadir ($n = 24$)On admissionQuadratic ($n = 24$)On admissionAt 2.6C-Reactive protein, mg/l ($n = 36$)On admissionQuadratic ($n = 24$)PeakDon admissionQuadratic ($n = 24$)Don admissionQuadratic ($n = 24$)Don admissionQuadratic ($n = 27$)On admissionQuadratic ($n = 27$)Quadratic ($n $	Mycophenolate mofetil	22/29 (76%)	
Everolimus $4/11$ (36%)Azathioprine $2/4$ (50%)Biological characteristicsCreatinine, μ mol/l ($n = 38$)On admission 150.5 ($107.3-307.8$)Peak 221.5 ($108.8-438.8$)NT-proBNP, ng/l 955.0 ($320.0-4079$)Peak ($n = 29$) 2257.0 ($638.0-7620.0$)White blood cells count, $10^9/l$ ($n = 36$)On admission 5.8 ($4.2-8.4$)Peak 8.9 ($5.7-13.3$)Lymphocyte count, $10^9/l$ ($n = 36$)On admission 0.65 ($0.40-0.91$)Nadir 0.48 ($0.28-0.72$)Haemoglobin, g/dl 0.48 ($0.28-0.72$)Haemoglobin, g/dl $0.43.8$ ($20.2-87.3$)Peak 100.2 ($34.8-217.8$)Procalcitonin, $\mu g/l$ ($n = 27$) 0.48 ($0.08-0.86$)	Tacrolimus	4/17 (23.5%)	
Azathioprine $2/4 (50\%)$ Biological characteristicsCreatinine, μ mol/l ($n = 38$)On admission $150.5 (107.3-307.8)$ Peak $221.5 (108.8-438.8)$ NT-proBNP, ng/lOn admission ($n = 26$) $955.0 (320.0-4079)$ Peak ($n = 29$) $2257.0 (638.0-7620.0)$ White blood cells count, $10^9/l (n = 36)$ On admission $5.8 (4.2-8.4)$ Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/l (n = 36)$ On admission $0.65 (0.40-0.91)$ Nadir $0.48 (0.28-0.72)$ Haemoglobin, g/dlOn admission ($n = 37$)Nadir ($n = 24$) 9.4 ± 2.6 C-Reactive protein, mg/l ($n = 36$)On admission $43.8 (20.2-87.3)$ PeakPeak $0.48 (0.08-0.86)$	Cyclosporine	1/22 (4.5%)	
Biological characteristics Creatinine, μ mol/l ($n = 38$) On admission150.5 (107.3–307.8) PeakPeak221.5 (108.8–438.8)NT-proBNP, ng/l On admission ($n = 26$)955.0 (320.0–4079) Peak ($n = 29$)Peak ($n = 29$)2257.0 (638.0–7620.0)White blood cells count, 10^9 /l ($n = 36$) On admission5.8 (4.2–8.4) PeakPeak8.9 (5.7–13.3)Lymphocyte count, 10^9 /l ($n = 36$) On admission0.65 (0.40–0.91) NadirNadir0.48 (0.28–0.72)Haemoglobin, g/dl On admission ($n = 37$)11.6 ± 2.0 9.4 ± 2.6C-Reactive protein, mg/l ($n = 36$) On admission9.4 ± 2.6C-Reactive protein, mg/l ($n = 36$) On admission43.8 (20.2–87.3) PeakProcalcitonin, μ g/l ($n = 27$) On admission0.48 (0.08–0.86)		4/11 (36%)	
Creatinine, μ mol/l ($n = 38$)On admission150.5 (107.3–307.8)Peak221.5 (108.8–438.8)NT-proBNP, ng/l0n admission ($n = 26$)955.0 (320.0–4079)Peak ($n = 29$)Peak ($n = 29$)2257.0 (638.0–7620.0)White blood cells count, 10 ⁹ /l ($n = 36$)On admissionOn admission5.8 (4.2–8.4)Peak8.9 (5.7–13.3)Lymphocyte count, 10 ⁹ /l ($n = 36$)On admissionOn admission0.65 (0.40–0.91)Nadir0.48 (0.28–0.72)Haemoglobin, g/dl0.48 (0.28–0.72)Haemoglobin, g/dl9.4 ± 2.6C-Reactive protein, mg/l ($n = 36$)0n admissionOn admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, μ g/l ($n = 27$)0.48 (0.08–0.86)	Azathioprine	2/4 (50%)	
On admission150.5 (107.3–307.8)Peak221.5 (108.8–438.8)NT-proBNP, ng/l955.0 (320.0–4079)Peak ($n = 29$)2257.0 (638.0–7620.0)White blood cells count, 10 ⁹ /l ($n = 36$)0n admissionOn admission5.8 (4.2–8.4)Peak8.9 (5.7–13.3)Lymphocyte count, 10 ⁹ /l ($n = 36$)0n admissionOn admission0.65 (0.40–0.91)Nadir0.48 (0.28–0.72)Haemoglobin, g/dl0n admission ($n = 37$)On admission ($n = 37$)11.6 ± 2.0Nadir ($n = 24$)9.4 ± 2.6C-Reactive protein, mg/l ($n = 36$)On admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, µg/l ($n = 27$)0.48 (0.08–0.86)			
Peak $221.5 (108.8-438.8)$ NT-proBNP, ng/l955.0 (320.0-4079)Peak $(n = 29)$ $2257.0 (638.0-7620.0)$ White blood cells count, $10^9/l (n = 36)$ 0n admissionOn admission $5.8 (4.2-8.4)$ Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/l (n = 36)$ 0n admissionOn admission $0.65 (0.40-0.91)$ Nadir $0.48 (0.28-0.72)$ Haemoglobin, g/dl0.48 (0.28-0.72)Haemoglobin, g/dl9.4 ± 2.6 C-Reactive protein, mg/l $(n = 36)$ On admission $43.8 (20.2-87.3)$ Peak100.2 (34.8-217.8)Procalcitonin, μ g/l $(n = 27)$ 0.48 $(0.08-0.86)$			
NT-proBNP, ng/l On admission $(n = 26)$ 955.0 (320.0-4079) Peak $(n = 29)$ Peak $(n = 29)$ 2257.0 (638.0-7620.0)White blood cells count, 10^9 /l $(n = 36)$ On admission5.8 (4.2-8.4) PeakPeak8.9 (5.7-13.3)Lymphocyte count, 10^9 /l $(n = 36)$ On admission0.65 (0.40-0.91) 0.48 (0.28-0.72)Haemoglobin, g/dl On admission $(n = 37)$ 11.6 \pm 2.0 9.4 \pm 2.6C-Reactive protein, mg/l $(n = 36)$ On admission43.8 (20.2-87.3) 100.2 (34.8-217.8)Procalcitonin, μ g/l $(n = 27)$ On admission0.48 (0.08-0.86)	On admission	. , , , , , , , , , , , , , , , , , , ,	
On admission $(n = 26)$ 955.0 (320.0-4079)Peak $(n = 29)$ 2257.0 (638.0-7620.0)White blood cells count, $10^9/I$ $(n = 36)$ On admissionOn admission5.8 (4.2-8.4)Peak8.9 (5.7-13.3)Lymphocyte count, $10^9/I$ $(n = 36)$ On admissionOn admission0.65 (0.40-0.91)Nadir0.48 (0.28-0.72)Haemoglobin, g/dl0.16 ± 2.0On admission $(n = 37)$ 11.6 ± 2.0Nadir $(n = 24)$ 9.4 ± 2.6C-Reactive protein, mg/I $(n = 36)$ On admissionOn admission43.8 (20.2-87.3)Peak100.2 (34.8-217.8)Procalcitonin, $\mu g/I$ $(n = 27)$ 0.48 (0.08-0.86)		221.5 (108.8–438.8)	
Peak $(n = 29)$ 2257.0 (638.0–7620.0)White blood cells count, 10^9 /l $(n = 36)$ On admission5.8 (4.2–8.4)Peak8.9 (5.7–13.3)Lymphocyte count, 10^9 /l $(n = 36)$ On admission0.65 (0.40–0.91)Nadir0.48 (0.28–0.72)Haemoglobin, g/dlOn admission $(n = 37)$ Nadir $(n = 24)$ 9.4 \pm 2.6C-Reactive protein, mg/l $(n = 36)$ On admissionA3.8 (20.2–87.3)PeakProcalcitonin, μ g/l $(n = 27)$ On admission0.48 (0.08–0.86)			
White blood cells count, $10^9/1$ ($n = 36$)On admission 5.8 ($4.2-8.4$)Peak 8.9 ($5.7-13.3$)Lymphocyte count, $10^9/1$ ($n = 36$) 0.65 ($0.40-0.91$)Nadir 0.48 ($0.28-0.72$)Haemoglobin, g/dl 0.48 ($0.28-0.72$)Haemoglobin, g/dl 11.6 ± 2.0 Nadir ($n = 24$) 9.4 ± 2.6 C-Reactive protein, mg/l ($n = 36$) $0n$ admissionOn admission 43.8 ($20.2-87.3$)Peak 100.2 ($34.8-217.8$)Procalcitonin, μ g/l ($n = 27$) 0.48 ($0.08-0.86$)			
On admission $5.8 (4.2-8.4)$ Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/I (n = 36)$ $0.65 (0.40-0.91)$ On admission $0.65 (0.40-0.91)$ Nadir $0.48 (0.28-0.72)$ Haemoglobin, g/dl $0.48 (0.28-0.72)$ Haemoglobin, g/dl 11.6 ± 2.0 On admission $(n = 37)$ 11.6 ± 2.6 C-Reactive protein, mg/l $(n = 36)$ $0.43 (20.2-87.3)$ Peak $100.2 (34.8-217.8)$ Procalcitonin, $\mu g/l (n = 27)$ $0.48 (0.08-0.86)$))
Peak $8.9 (5.7-13.3)$ Lymphocyte count, $10^9/I (n = 36)$ 0.65 (0.40-0.91)On admission0.65 (0.40-0.91)Nadir0.48 (0.28-0.72)Haemoglobin, g/dl0.48 (0.28-0.72)On admission $(n = 37)$ 11.6 ± 2.0 Nadir $(n = 24)$ 9.4 ± 2.6 C-Reactive protein, mg/l $(n = 36)$ 0n admissionOn admission $43.8 (20.2-87.3)$ Peak $100.2 (34.8-217.8)$ Procalcitonin, μ g/l $(n = 27)$ 0.48 $(0.08-0.86)$			
Lymphocyte count, $10^{9}/l$ ($n = 36$) On admission 0.65 (0.40–0.91) Nadir 0.48 (0.28–0.72) Haemoglobin, g/dl On admission ($n = 37$) 11.6 ± 2.0 Nadir ($n = 24$) 9.4 ± 2.6 C-Reactive protein, mg/l ($n = 36$) On admission 43.8 (20.2–87.3) Peak 100.2 (34.8–217.8) Procalcitonin, µg/l ($n = 27$) On admission 0.48 (0.08–0.86)			
On admission $0.65 (0.40-0.91)$ Nadir $0.48 (0.28-0.72)$ Haemoglobin, g/dl 11.6 ± 2.0 On admission $(n = 37)$ 11.6 ± 2.6 C-Reactive protein, mg/l $(n = 36)$ 9.4 ± 2.6 On admission $43.8 (20.2-87.3)$ Peak $100.2 (34.8-217.8)$ Procalcitonin, μ g/l $(n = 27)$ $0.48 (0.08-0.86)$		8.9 (5.7–13.3)	
Nadir 0.48 ($0.28-0.72$)Haemoglobin, g/dl $0n$ admission ($n = 37$) 11.6 ± 2.0 Nadir ($n = 24$) 9.4 ± 2.6 C-Reactive protein, mg/l ($n = 36$) $0n$ admissionOn admission 43.8 ($20.2-87.3$)Peak 100.2 ($34.8-217.8$)Procalcitonin, μ g/l ($n = 27$) 0.48 ($0.08-0.86$)		/	
Haemoglobin, g/dl11.6 \pm 2.0On admission (n = 37)11.6 \pm 2.0Nadir (n = 24)9.4 \pm 2.6C-Reactive protein, mg/l (n = 36)43.8 (20.2–87.3)On admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, μ g/l (n = 27)0.48 (0.08–0.86)		. , ,	
On admission $(n = 37)$ 11.6 \pm 2.0Nadir $(n = 24)$ 9.4 \pm 2.6C-Reactive protein, mg/l $(n = 36)$ 43.8 (20.2–87.3)On admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, μ g/l $(n = 27)$ 0.48 (0.08–0.86)		0.48 (0.28–0.72)	
Nadir $(n = 24)$ 9.4 ± 2.6 C-Reactive protein, mg/l $(n = 36)$ 43.8 (20.2–87.3)On admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, μ g/l $(n = 27)$ 0.48 (0.08–0.86)		44.6 + 2.0	
C-Reactive protein, mg/l $(n = 36)$ On admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, μ g/l $(n = 27)$ 0.48 (0.08–0.86)			
On admission43.8 (20.2–87.3)Peak100.2 (34.8–217.8)Procalcitonin, μg/l (n = 27)0.48 (0.08–0.86)	· · · · ·	9.4 ± 2.6	
Peak 100.2 (34.8–217.8) Procalcitonin, μg/l (n = 27) 0.48 (0.08–0.86)			
Procalcitonin, $μg/l$ ($n = 27$) On admission 0.48 (0.08–0.86)			
On admission 0.48 (0.08–0.86)		100.2 (34.8–217.8)	
геак 0.69 (0.12–1.50)		· · · · · · · · · · · · · · · · · · ·	
	геак	0.09 (0.12–1.50)	

Table 2. Patient presentation, management and outcomes.

21/39 (53.8%)

18/39 (46.2%) 21/39 (53.8%)

5/39 (12.8%)

2/39 (5.1%) 5/39 (12.8%)

2/39 (5.1%)

13/39 (33.3%)

33/39 (84.6%)

6.0 (3.0–13.0)

25/33 (75.8%)

14/33 (42.4%)

Clinical symptoms prior to admission

Respiratory tract symptoms (cough, expectoration, nasal congestion)

Gastrointestinal symptoms

Delay between symptoms

Lung overall involvement

(diarrhoea, vomiting) Chest CT performed

onset and CT, day Lung bilateral involvement

Fever Dysphoea

Myalgia

Anosmia

Ageusia

Headache

<10%

Fibrinogen, g/l	
On admission $(n = 25)$	4.9 (3.7–6.4)
Peak ($n = 27$)	6.1 (5.2–7.9)
D-Dimer, ng/ml ($n = 38$)	
On admission $(n = 13)$	1357.0
	(1001.0–2550.0)
Peak ($n = 21$)	2000.0
	(980.5–5301.0)
Troponin peak	
High sensitivity,	44.2
ng/l (n = 21/27)	(17.5–75.0)
Nonhigh sensitivity,	0.03
μ g/l (n = 11/13)	(0.01–0.09)
In-hospital outcomes	
Need for noninvasive ventilation	7/39 (17.9%)
Duration of noninvasive	4.0 ± 2.7
ventilation, day	
Need for mechanical ventilation	8/39 (20.5%)
Duration of mechanical	17.6 ± 15.2
ventilation, days	
Acute kidney injury	22/39 (56.4%)
Dialysis in patient not previously	6/35 (17.1%)
on dialysis programme	
Death	10/39 (25.6%)
Death or mechanical ventilation	13/39 (33.3%)

COVID 19, coronavirus disease 2019; NT-proBNP, N-terminal pro-B type natriuretic peptide; PCR, polymerase chain reaction.

Variables are provided as mean \pm standard deviation or median (interguartile 25-75%).

(OR 3.60, 95% CI 1.43–9.06, $I^2 = 0\%$, P = 0.006) and chronic kidney disease stage III or higher (OR 3.79 95% CI 1.39–10.31, $I^2 = 0\%$, P = 0.009; Fig. 2). Male gender, pre-existing hypertension, severe cardiac allograft vasculopathy (ISHLT CAV 3), use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and single or dual immunosuppressive therapy (vs. triple or quadruple regimens) were not significantly associated with mortality. There was no evidence of publication bias (Fig. S3).

The main finding of our study is that the observed rates of death and death or need for mechanical ventilation in laboratory-confirmed COVID-19 HT recipients were 25.6% and 33.3%, respectively. This finding is consistent with previous reports in heart and kidney transplant population. Thus, the clinical course of COVID-19 is more aggressive in HT recipients than in the general population while the death rate among solid organ transplant recipients is higher with COVID-19 than

	Table 3. Markers	f risk of death	or need for	mechanical ventilation	
--	------------------	-----------------	-------------	------------------------	--

Variables	Death or mechanical ventilation $(n = 13)$	No death nor mechanical ventilation $(n = 27)$	<i>P</i> -value
Age, years	55.8 ± 11.2	53.2 ± 16.7	0.97
Male sex	11 (84.6%)	15 (55.6%)	0.15
Blood type O (vs. other blood types)	4 (30.8%)	10 (37.0%)	0.73
Blood type A (vs. other blood types)	7 (53.8%)	9 (33.3%)	0.21
Pretransplant ischaemic cardiomyopathy	5 (38.5%)	6 (22.2%)	0.28
Time post-transplantation, years	4.3 (1.4–8.8)	5.0 (1.9–9.0)	0.65
History of acute rejection	8 (61.5%)	17 (63.0%)	0.99
History of ISHLT cardiac	2 (15.4%)	7 (25.9%)	0.69
allograft vasculopathy 2 or 3			
Cytomegalovirus positive status	10/12 (83.3%)	16/26 (61.5%)	0.28
Epstein Barr Virus positive status	12/12 (100.0%)	23/25 (92%)	0.99
Chronic kidney disease	9 (69.2%)	12 (44.4%)	0.31
stage III or higher			
Diabetes mellitus	7 (53.8%)	9 (33.3%)	0.25
Dyslipidaemia	5 (38.5%)	7 (25.9%)	0.46
Hypertension	9 (69.2%)	19 (70.3%)	0.99
Body mass index, kg/m ²	26.3 ± 4.3	27.3 ± 6.2	0.60
Baseline medication			
ACE-I or ARB	7 (53.8%)	9 (33.3%)	0.25
Prednisone dosage >5 mg per day	6 (46.2%)	12 (44.4%)	0.99
Dual immunosuppressive therapy	1 (7.7%)	4 (14.8%)	0.65
CT lung involvement ≥50%	8/12 (66.7%)	3/21 (14.3%)	0.006
Laboratory variables at admission			
Creatinine, µmol/l	298.0 (149.0–522.0)	137.0 (97.5–236.5)	0.07
C-reactive protein, mg/l	75.5 (44.3–182.5)	31.9 (3.0–62.6)	0.01
NT-proBNP, ng/l	895.0 (429.8–3555.0)	1084.0 (433.5–5847.0)	0.89
White blood cell count, 10 ⁹ /l	6.8 (4.8–11.3)	5.7 (4.0–7.0)	0.16
Lymphocyte count, 10 ⁹ /l	0.53 (0.30–0.84)	0.72 (0.43–1.02)	0.23
Procalcitonin, μg/l	0.80 (0.33–1.00)	0.11 (0.04–0.72)	0.054
Fibrinogen, g/l	5.1 (3.4–7.8)	4.9 (3.8–6.1)	0.82
D-dimer, ng/ml	1524.0 (1268.0–5308.0)	1156 (340.0–2151.0)	0.22

ISHLT, International Society for Heart and Lung Transplantation.

with other RNA respiratory viral infections such as influenza [54, 55]. However, as detection of SARS-CoV-2 infection was not performed throughout the entire cohort, the death rate in our study may have overestimated the case fatality rate of COVID-19. For this reason, we assessed the excess mortality because of COVID-19 in the entire cohort of HT recipients followed in our three centres. By comparing the number of deaths from March to June 2020, and from March to June 2019, we observed an overall 56% excess mortality during the early outbreak of COVID, which corresponded to the number of COVID-19-attributed deaths, suggesting that the excess mortality was driven by COVID-19-related deaths and not by an increase in deaths from other causes.

HT recipients with COVID-19 had similar initial clinical manifestations to the general population with

fever, dyspnoea and respiratory symptoms even if these symptoms were less common [4,17,18,54].

Another finding of our case series and meta-analysis is that the initial disease severity and comorbidities are predictors of COVID-19 outcomes. C-reactive protein and lung involvement extent at hospital admission were identified to be associated with the occurrence of death or need for mechanical ventilation, while meta-analysis showed that diabetes mellitus and chronic kidney disease stage III or higher were altogether increasing the risk of death. The link between pre-existing comorbidities and more severe form of COVID-19 has been consistently although the reported, specific pathophysiological mechanisms behind this association remain to be better defined. Diabetes mellitus and chronic kidney disease, in particular, have been reported in numerous studies and meta-analyses as increasing




Figure 1 Heart transplant recipient survival from March to June 2019 and March to June 2020.

mortality in the general population infected with COVID-19 [56,57]. Both comorbidities may be associated with dysfunction of the immune system and enhanced inflammation, which could partly explain the increased severity and mortality in COVID-19 patients [58,59]. Notably, hypertension which is the most common underlying comorbidity in HT recipients was not associated with death in the meta-analysis. Although the reason for this specific result is not clear, it may be related to the remarkably high proportion of HT recipients with hypertension. Similarly, there was no relationship between renin-angiotensin system (RAS) blocker use and death. A potential harmful effect of these agents has been speculated in the setting of COVID-19 since it has been established that SARS-CoV-2 infects human cells through the binding of its Spike (S) protein to ACE2, acting as co-receptor for cellular viral entry, while animal studies have suggested a potential up regulation of ACE2 expression by RAS blockers [60,61]. No significant association of RAS blockers on COVID-19related mortality was present in our study focusing on HT recipients, which is consistent with some other reports in the general population [62]. Randomized trials such as the ACE inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic (ACORES-2, NCT04329195) are ongoing to further evaluate this issue.

No evidence-based recommendations are available on the management of the immunosuppressive treatment among HT recipients affected with COVID-19. Immunosuppressive regimen was downgraded in 72.5% of patients included in our case series. Antimetabolites increasing COVID-19-induced lymphopenia potentially induce SARS-CoV-2 replication. While mTOR inhibitors have an antiviral effect on CMV, there are no data supporting the efficacy and safety of mTOR inhibitors as antiviral therapy for COVID-19. Experimental models have shown that calcineurin inhibitors block SARS-CoV replication in vitro but clinical data supporting safety and efficacy of an immunosuppressive treatment based on cyclosporine in kidney transplant recipients remain weak [63]. Corticosteroids use has the potential to modulate the inflammatory response but has been associated with an increase in viral shedding. In the RECOVERY trial, the use of dexamethasone resulted in lower mortality among patients receiving respiratory support [64]. Further investigations are warranted to address the issue of immunosuppressive treatment's management in the specific setting of COVID-19.

The limitations of this study are those associated with small observational studies. The association between baseline presentation and adverse outcomes was only assessed in univariate analysis as the limited sample size of our case series and number of events prevented the possibility to carry out a multivariable analysis. Moreover, we mostly included symptomatic patients which may have led to an overestimation of the case fatality of the disease. The prevalence of asymptomatic SARS-

Granger et al.

study or Subgroup	Diabetes m Events	Total	No diab Ever			Weight		dds Ratio I, Fixed, 95% Cl	Odds Ratio M-H, Fixed, 95%	CI
lottio et al.,	5	8		9	37	25.4%		19 [1.03, 26.11]		•
rench multicenter registry	5	16		5	24	58.2%		.73 [0.41, 7.33]		
arcia-Cosio et al.	1	2		3	11	9.8%		67 [0.12, 57.62]		
linghvi et al.,	5	12		0	10			0 [0.73, 322.88]		· · · ·
	-									
otal (95% CI)		38			82	100.0%	3.	.60 [1.43, 9.06]	▼	
otal events	16			17						
leterogeneity: Chi ² = 2.10, df = est for overall effect Z = 2.72			6						0.01 0.1 1	10 10
	Stade III		No stade	III CKD			Odde	Ratio	DM better DM w Odds Ratio	0128
Study or Subgroup	Events	Total	Events	Tota	Weig	int M		ced, 95% Cl	M-H, Fixed, 95%	сі
Bottio et al.,	6	13	1	13				02, 103.95]		•
French multicenter registry	7	21	3	18	49.9	9%	2.50 [0	0.54, 11.62]		
Garcia-Cosio et al.,	2	6	2	7	28.5	5%	1.25 [0	0.12, 13.24]		
Singhvi et al.,	5	14	0	8	9.2	2% 9	9.84 [0.	47, 205.62]		•
fotal (95% CI)		54		46	5 100.0	0%	3.79 [1	.39, 10.31]		
fotal events	20		6							
Heterogeneity: Chi* = 2.22, d).53); P=						0.0	1 0,1 1	10 10
Test for overall effect Z = 2.6	1 (P = 0.00)	09)						0.0	CKD better CKD w	
	Male ger	vder I	emale ge	nder		Ode	ds Rati	0	Odds Ratio	
Study or Subgroup	Events		Events	Total 1	Neight				M-H, Fixed, 95% Cl	
Bottio et al.	12	37	2	10	39.2%		[0.35,			
French multicenter registry	9	26	1	13	16.0%		[0.71.			•
Garcia-Cosio et al.,	4	10	ö	3	8.0%		0.20, 1			
Singhvi et al.,	3	14	2	8	36.8%		2 [0.11			-
					100 000		-	-		
Total (95% CI)	20	87	5	34	100.0%	2.46	6 [0. 89,	0.76]		
Total events Heterogeneity: Chi ^a = 2.08, d	28	60\ IZ = 1	-							
Test for overall effect Z = 1.7	-		0.76					0.01 Fei	0.1 i male gender worse Male geno	10 10 Jerworse
	stemic hyp	ortoneion	Mo eue	temic hyp	artoneiou			Odds Ratio	Odds Ratio	101 110130
Study or Subgroup	Events	Tot		ents				-H, Fixed, 95% Cl	M-H, Fixed, 95%	CI
Bottio et al.,	8		30	6		17 49.	.1%	0.67 [0.18, 2.40]		
French multicenter registry	6		28	4		11 39.	.5%	0.48 [0.10, 2.19]		
Garcia-Cosio et al.,	3		7							
			1	1		6 5.	4% 3	3.75 [0.27, 51.37]		•
Singhvi et al.,	5	3	21	0				3.75 [0.27, 51.37] 1.00 [0.04, 28.30]		
			21			1 6.	.0% 1	1.00 [0.04, 28.30]		
Total (95% CI)	5			0			.0% 1		•	·
Total (95% CI) Total events	5	1	21			1 6.	.0% 1	0.78 (0.33, 1.85)	-	
Total (95% CI)	5 22 3 (P = 0.60);	1	21	0		1 6.	.0% 1	0.78 (0.33, 1.85)	0.01 0.1	10 1
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df = 1	22 3 (P = 0.60); P = 0.57)	P=0%	21 86	11		1 6. 35 100	.0% 1).0%	1.00 [0.04, 28.30] 0.78 [0.33, 1.85]	Hypertension better Hyper	
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df = Test for overall effect Z = 0.57 (f	5 22 3 (P = 0.60);	P=0%	21	0 11 CAV III		1 6. 35 100	.0% 1 0.0%	1.00 (0.04, 28.30) 0.78 (0.33, 1.85) atio	Hypertension better Hyper Odds Ratio	
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df = 1	22 3 (P = 0.60); P = 0.57) ISLTH CA	P=0% AV Ⅲ	21 86 No ISLTH	0 11 CAV III		1 6. 35 100 0. 1. M-H,	.0% 1).0% ddsRa I, Fixed,	1.00 [0.04, 28.30] 0.78 [0.33, 1.85]	Hypertension better Hyper	
Total (95% CI) Total events Heterogeneity: Chi [®] = 1.86, df =: Test for overall effect Z = 0.57 (f Study or Subgroup	5 22 3 (P = 0.80); P = 0.57) ISLTH C/ Events	P=0% AVIII Total	21 86 No ISL TH Events	0 11 CAV III Total		1 6. 35 100 0. at M-H,	.0% 1).0% ddds Ra I, Fixed, Notes	1.00 [0.04, 28:30] 0.78 [0.33, 1.85] ntio , 95% CI	Hypertension better Hyper Odds Ratio	
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df = Test for overall effect Z = 0.57 (f Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al.,	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0	P=0% AVIII Total 0 9 2	21 86 No ISLTH Events 0 8 4	0 11 CAV III Total 0 31 11	Weigh 60.09 32.29	1 6. 35 100 at <u>M-H</u> , 56 0. 56 0.	.0% 1 0.0% dds Ra 1, Fixed, Not es .82 [0.1 .33 [0.0	1.00 [0.04, 28:30] 0.78 [0.33, 1.85] stio .95% Cl timable 4, 4.80] 01, 8:63]	Hypertension better Hyper Odds Ratio	
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df = Test for overall effect Z = 0.57 (f Study or Subgroup Bottio et al., French multicenter registry	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2	P=0% AV III Total 0 9	21 86 No ISLTH Events 0 8	0 11 CAV III Total 0 31	Weigh	1 6. 35 100 at <u>M-H</u> , 56 0. 56 0.	.0% 1 0.0% dds Ra 1, Fixed, Not es .82 [0.1 .33 [0.0	1.00 [0.04, 28:30] 0.78 [0.33, 1.85] ntio , 95% CI timable 4, 4.80]	Hypertension better Hyper Odds Ratio	
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df = Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicentor registry Garcia-Cosio et al., Singhvi et al.,	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0	P=0% AV III 0 9 2 2	21 86 No ISLTH Events 0 8 4	0 11 <u>Total</u> 0 31 11 20	Weigh 80.09 32.29 7.89	1 6. 35 100 0 t M-H, 5 0. 5 0. 5 4.0	.0% 1),0% dds Ra <u>, Fixed</u> Not es .82 [0.1 .33 [0.0 0 [0.20	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio .95% CI timable [4, 4.80] 11, 8.63] .78.79]	Hypertension better Hyper Odds Ratio	
Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI)	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0	P=0% AVIII Total 0 9 2	21 86 No ISLTH Events 0 8 4 4 4	0 11 <u>Total</u> 0 31 11 20	Weigh 60.09 32.29	1 6. 35 100 0 t M-H, 5 0. 5 0. 5 4.0	.0% 1),0% dds Ra <u>, Fixed</u> Not es .82 [0.1 .33 [0.0 0 [0.20	1.00 [0.04, 28:30] 0.78 [0.33, 1.85] stio .95% Cl timable 4, 4.80] 01, 8:63]	Hypertension better Hyper Odds Ratio	
Total (95% CI) Total events Heterogeneity: Chi [®] = 1.86, df =: Test for overall effect Z = 0.57 (f Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0 1 3	P=0% AV III 0 9 2 2 13	21 86 No ISLTH <u>Events</u> 0 8 4 4 4	0 11 <u>Total</u> 0 31 11 20	Weigh 80.09 32.29 7.89	1 6. 35 100 0 t M-H, 5 0. 5 0. 5 4.0	.0% 1),0% dds Ra <u>, Fixed</u> Not es .82 [0.1 .33 [0.0 0 [0.20	1.00 [0.04, 28:30] 0.78 [0.33, 1.85] attio .95% CI .timable 4, 4.80] .1, 8:63] .78.79] .4, 3.42]	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI	lension worse
Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI)	5 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0 1 3 df = 2 (P = 0	P=0% AV III 0 9 2 2 13 0.52); P=	21 86 No ISLTH <u>Events</u> 0 8 4 4 4	0 11 <u>Total</u> 0 31 11 20	Weigh 80.09 32.29 7.89	1 6. 35 100 0 t M-H, 5 0. 5 0. 5 4.0	.0% 1),0% dds Ra <u>, Fixed</u> Not es .82 [0.1 .33 [0.0 0 [0.20	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio .95% CI timable [4, 4.80] 11, 8.63] .78.79]	Hypertension better Hypert Odds Ratio M.H, Fixed, 95% CI	10 10
Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.88, df =: Test for overall effect Z = 0.57 (f <u>Study or Subgroup</u> Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.33, c Test for overall effect Z = 0.1	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0 1 1 stf = 2 (P = 0 14 (P = 0.85)	P=0% AV III 0 9 2 2 13 0.52); P=	21 86 No ISLTH <u>Events</u> 0 8 4 4 4 16 0%	0 11 Total 0 31 11 20 62	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 at <u>M-H</u> , 5 0. 5 4.0 5 0.5	.0% 1),0% dds Ra <u>, Fixed</u> Not es .82 [0.1 .33 [0.0 0 [0.20	1.00 [0.04, 28:30] 0.78 [0.33, 1.85] attio .95% CI timable 4, 4.80] 01, 8:63] 0, 78.79] 44, 3.42] 0.01	Hypertension better Hypert Odds Ratio M.H, Fixed, 95% CI	10 10
Total (95% CI) Total events Heterogeneity: Chi [®] = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Costo et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi [®] = 1.33, d Test for overall effect Z = 0.1 Ba	5 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0 1 3 df = 2 (P = 0	P=0% AV III Total 0 9 2 2 13 0.52); P = 0) (CE-I/ARB:	21 86 No ISLTH <u>Events</u> 0 8 4 4 4 16 0%	0 11 <u>Total</u> 0 31 11 20	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 at M-H, % 0. % 4.0 % 0.9	.0% 1).0% ddds Ra , Fixed, Not es .82 [0.1 .33 [0.0 00 [0.20 91 [0.2	1.00 [0.04, 28:30] 0.78 [0.33, 1.85] attio .95% CI .timable 4, 4.80] .1, 8:63] .78.79] .4, 3.42]	Hypertension better Hypert Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio	10 10
Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.33, d Test for overall effect. Z = 0.1 Ba Study or Subgroup Bottio et al.,	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0 1 1 df = 2 (P = 0 4 (P = 0.85 ackground A Events 0	P = 0% Total 0 9 2 13 0.52); P = 0.52); P = 0.52); Total	21 86 No ISLTH <u>Events</u> 0 4 4 4 16 0% 8 No base tal 0	0 11 CAV III 0 311 11 20 62 62 Events 0	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 at M-H, % 0. % 0.9 % 0.9	.0% 1).0% Adds Ra <u>, Fixed</u> , Not es .82 [0.1 .33 [0.0 00 [0.20 91 [0.2	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio <u>95% CI</u> timable 4, 4.80] 11, 8.63] 0, 78.79] 4, 3.42] 0.01 Odds Ratio M-H, Fixed, 95% C Not estimable	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95%	10 11 AV III worse
Total (95% CI) Total events Heterogeneily: Chi ⁹ = 1.86, df =: Test for overall effect: Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.33, c Test for overall effect: Z = 0.1 Ba Study or Subgroup Bottio et al., French multicenter registry	5 22 3 (P = 0.60); P = 0.57) ISLTH C: Events 0 0 1 if = 2 (P = 0 6 if = 2 (P = 0 4 (P = 0.85) ackground A Events 0 5 5 5 5 5 5 5 5 5 5 5 5 5	P = 0% Total 0 9 2 13 0.52); P = 0.52); P = 0.52); Total	21 86 No ISLTH Events 0 8 4 4 4 0% 16 0% 8 No bao 17	0 11 CAV III Total 0 31 11 20 62 ckground / Events 0 5	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 at M.H. 5 0.9 5 4.0 5 4.0 5 0.9 5 0.9 10 10 10 10 10 10 10 10 10 10	.0% 1).0% ddds Ra , Fixed, Not es .82 [0.1 .33 [0.0 00 [0.20 91 [0.2	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] 1.00 0.78 [0.33, 1.85] 1.95% CI 1.00 1.95% CI 1.50 [0.36, 8.32] 1.50 [0.36, 8.32]	Hypertension better Hypert Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95%	10 10
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ^a = 1.33, c Test for overall effect Z = 0.1 Batto et al., French multicenter registry Garcia-Cosio et al., Study or Subgroup Bottio et al.,	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0 1 3 af = 2 (P = 0 8 4 (P = 0.89) 0 1 4 (P = 0.80) 0 5 0 1 5 0 1 5 0 1 1 5 0 1 5 0 1 5 1 1	P = 0% AV III 0 9 2 2 13 0.52); P = 3) ICE-I/ARB: To	21 86 No ISLTH Events 0 8 4 4 16 0% 8 No base tal 0 17 0	0 11 CAV III Total 0 31 11 20 62 Exercised of the second of the	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 t M-H, 5 0. 5 4.0 5 0.9 5 4.0 5 0.9 10 10 10 10 10 10 10 10 10 10	dds Ra , fixed, Notes .82 (0.1 .33 (0.0 .00 (0.20 .91 (0.2 .91 (0.2 .91 (0.2	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio .95% CI timable [4, 4.80] 11, 8.63] 0, 78.79] 44, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% C Not estimable 1.50 [0.36, 6.32] Not estimable	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95%	10 10
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ^a = 1.33, c Test for overall effect Z = 0.1 Bottio et al., French multicenter registry Garcia-Cosio et al., Study or Subgroup	5 22 3 (P = 0.60); P = 0.57) ISLTH C: Events 0 0 1 if = 2 (P = 0 6 if = 2 (P = 0 4 (P = 0.85) ackground A Events 0 5 5 5 5 5 5 5 5 5 5 5 5 5	P = 0% AV III 0 9 2 2 13 0.52); P = 3) ICE-I/ARB: To	21 86 No ISLTH Events 0 8 4 4 4 0% 16 0% 8 No bao 17	0 11 CAV III Total 0 31 11 20 62 Skground / Events 0 5	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 t M-H, 5 0. 5 4.0 5 0.9 5 4.0 5 0.9 10 10 10 10 10 10 10 10 10 10	.0% 1).0% Adds Ra <u>, Fixed</u> , Not es .82 [0.1 .33 [0.0 00 [0.20 91 [0.2	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] 1.00 0.78 [0.33, 1.85] 1.95% CI 1.00 1.95% CI 1.50 [0.36, 8.32] 1.50 [0.36, 8.32]	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95%	10 10
Total (95% CI) Total events Heterogeneity: Chi [®] = 1.86, df =: Test for overall effect Z = 0.57 (f Study or Subgroup Botto et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi [®] = 1.33, c Test for overall effect Z = 0.1	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 2 0 1 3 af = 2 (P = 0 8 4 (P = 0.89) 0 1 4 (P = 0.80) 0 5 0 1 5 0 1 5 0 1 1 5 0 1 5 0 1 5 1 1	P = 0% AV III 0 9 2 13 0.52); P = 0. (CE-I/ARB: To	21 86 No ISLTH Events 0 8 4 4 16 0% 8 No base tal 0 17 0	0 11 CAV III Total 0 31 11 20 62 Exercised of the second of the	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 t M-H, 5 0. 5 4.0 5 0.9 5 4.0 5 0.9 10 10 10 10 10 10 10 10 10 10	.0% 1 .0% Midds Ra , <u>Fixed</u> , Not es .82 (0.1 .33 (0.0 0 (0.20 91 (0.2 91 (0.2 91 (0.2 91 (0.2	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio .95% CI timable [4, 4.80] 11, 8.63] 0, 78.79] 44, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% C Not estimable 1.50 [0.36, 6.32] Not estimable	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 959	10 10
Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.33, d Test for overall effect Z = 0.1 Ba Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events	5 22 3 (P = 0.60); P = 0.57) ISLTH C/ Events 0 0 1 1 3 3 3 4 (P = 0.89 0 1 1 3 3 6 1 2 0 1 1 2 2 0 0 1 1 2 2 2 2 0 0 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2	P = 0% AV III 0 9 2 2 13 0.52); P = 0) (CE-I/ARB: To	21 86 No ISLTH Events 0 8 4 4 4 0 % 16 0 % 8 No bac tal 0 17 0 17 0 11	0 11 CAV III Total 0 31 11 20 62 Exercised of the second of the	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 0. 10 10 10 10 10 10 10 10 10 10	.0% 1 .0% Midds Ra , <u>Fixed</u> , Not es .82 (0.1 .33 (0.0 0 (0.20 91 (0.2 91 (0.2 91 (0.2 91 (0.2	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio <u>.95% CI</u> timable 4, 4.80] 01, 8.63] 0, 78.79] 4, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% C Not estimable 1.50 [0.36, 8.32 Not estimable 0.59 [0.08, 4.50]	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 959	10 10
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df =: Test for overall effect Z = 0.57 (f Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ^a = 1.33, d Test for overall effect. Z = 0.1 Ba Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ^a = 0.54, df = 1	5 22 3 (P = 0.60); P = 0.57) ISLTH C: Events 2 0 1 if = 2 (P = 0 4 (P = 0.65) if = 2 (P = 0 4 (P = 0.65) 0 2 1 (P = 0.60); 1 (P = 0.60); 1 (P = 0.60); 2 0 1 (P = 0.60); (P = 0.57) 1 (P = 0.60); (P = 0.57) 2 0 1 (P = 0.60); (P = 0.57) 2 0 1 (P = 0.60); (P = 0.57) 2 0 1 (P = 0.60); (P = 0.57) 2 0 1 (P = 0.60); (P = 0.60); (P = 0.57) 2 0 1 (P = 0.60); (P	P = 0% AV III 0 9 2 2 13 0.52); P = 0) (CE-I/ARB: To	21 86 No ISLTH Events 0 8 4 4 4 0 % 16 0 % 8 No bac tal 0 17 0 17 0 11	0 11 CAV III Total 0 31 11 20 62 Events 0 5 0 3	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 0. 10 10 10 10 10 10 10 10 10 10	.0% 1 .0% Midds Ra , <u>Fixed</u> , Not es .82 (0.1 .33 (0.0 0 (0.20 91 (0.2 91 (0.2 91 (0.2 91 (0.2	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio <u>.95% CI</u> timable 4, 4.80] 01, 8.63] 0, 78.79] 4, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% C Not estimable 1.50 [0.36, 8.32 Not estimable 0.59 [0.08, 4.50]	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH CAV III better M.H, Fixed, 959	10 11 AV III worse
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df =: Test for overall effect Z = 0.57 (f Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ^a = 1.33, d Test for overall effect. Z = 0.1 Ba Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ^a = 0.54, df = 1	5 22 3 (P = 0.60); P = 0.57) ISLTH C: Events 2 0 1 if = 2 (P = 0 4 (P = 0.65) if = 2 (P = 0 4 (P = 0.65) 0 2 1 (P = 0.60); 1 (P = 0.60); 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 1 (P = 0.60); 2 0 1 (P = 0.60); 2 (P = 0.60); 2 (P = 0.60); 1 (P = 0.60); 2 (P = 0.60); (P = 0.60);	P = 0% AV III 0 9 2 2 13 0.52); P = 0) (CE-I/ARB: To	21 86 No ISLTH Events 0 8 4 4 4 0 % 16 0 % 8 No bac tal 0 17 0 17 0 11	0 11 CAV III Total 0 31 11 20 62 Events 0 5 0 3	Weigh 80.09 32.29 7.89 100.0 9	1 6. 35 100 0. 10 10 10 10 10 10 10 10 10 10	.0% 1 .0% Midds Ra , <u>Fixed</u> , Not es .82 (0.1 .33 (0.0 0 (0.20 91 (0.2 91 (0.2 91 (0.2 91 (0.2	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio <u>.95% CI</u> timable 4, 4.80] 01, 8.63] 0, 78.79] 4, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% C Not estimable 1.50 [0.36, 8.32 Not estimable 0.59 [0.08, 4.50]	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 959	10 11 10 11 10 11 10 11 10 1
Total (95% CI) Total events Heterogeneity: Chi ² = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 1.33, d Test for overall effect Z = 0.1 Battudy or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 0.54, df = 1 Test for overall effect Z = 0.15 (P	5 22 3 (P = 0.60); P = 0.57) ISLTH C: Events 2 0 1 if = 2 (P = 0 4 (P = 0.65) if = 2 (P = 0 4 (P = 0.65) 0 2 1 (P = 0.60); 1 (P = 0.60); 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 2 0 1 (P = 0.60); 1 (P = 0.60); 2 0 1 (P = 0.60); 2 (P = 0.60); 2 (P = 0.60); 1 (P = 0.60); 2 (P = 0.60); (P = 0.60);	P = 0% AV III 0 9 2 2 13 0.52); P = 0 (CE-I/ARB: <u>To</u>	21 86 No ISLTH Events 0 8 4 4 16 0% 8 No base tal 0 17 0 11 28	0 11 CAV III Total 0 31 11 20 62 Events 0 5 0 3	Weigh 80.09 32.29 7.89 100.0 9 100.0 9 100.0 9	1 6. 35 100 t M-H, 5 0. 5 4.0 5 0. 5 4.0 10 4.0 11 4 34 10	.0% 1 .0% Midds Ra , <u>Fixed</u> , Not es .82 (0.1 .33 (0.0 0 (0.20 91 (0.2 91 (0.2 91 (0.2 91 (0.2	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio <u>.95% CI</u> timable 4, 4.80] 01, 8.63] 0, 78.79] 4, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% C Not estimable 1.50 [0.36, 8.32 Not estimable 0.59 [0.08, 4.50]	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95%	10 11 10 11 AV III worse CI
Total (95% CI) Total events Heterogeneity: Chi ² = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 1.33, d Test for overall effect Z = 0.1 Battudy or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 0.54, df = 1 Test for overall effect Z = 0.15 (P	5 22 3 (P = 0.60); P = 0.57) ISLTH CJ Events 0 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 2 0 1 1 2 0 1 2 0 1 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 1 2 0 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 2 0 1 1 2 2 (P = 0 8 5 0 2 1 2 (P = 0.895 0 2 0 1 4 (P = 0.895 0 2 0 1 4 (P = 0.895 5 0 2 0 2 0 1 2 (P = 0.465, 1 2 0 2 0 1 4 (P = 0.895 2 2 2 2 (P = 0.465, 1 2 2 2 2 2 2 2 2 2 2 2 2 2	P = 0% AV III 0 9 2 2 13 0.52); P = 13 0.52); P = 0 (CE-I/ARB: To P = 0%	21 86 No ISLTH Events 0 8 4 4 16 0% 8 No base tal 0 17 0 11 28	0 11 CAV III Total 0 31 11 20 62 Events 0 5 0 3 8	Weigh 60.09 7.89 100.09 ACE-I/AR 10 0.09	1 6. 35 100 t M-H, 5 0. 5 4.0 5 0. 5 4.0 10 4.0 11 4 34 10	.0% 1 0.0% 1 0.0	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio .95% CI timable [4, 4.80] 11, 8.63] 0, 78.79] 4, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% C Not estimable 0.59 [0.08, 4.50 1.09 [0.34, 3.48]	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95% 0.01 0.1 ACE-I/ARBs better ACE- Odds Ratik	10 11 10 11 AV III worse 4 CI
Total (95% CI) Total events Heterogeneity: Chi ² = 1.86, df =: Test for overall effect $Z = 0.57$ (f) Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 1.33, d Test for overall effect $Z = 0.11$ Ba Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 0.54, df = 1 Test for overall effect $Z = 0.15$ (P)	5 22 3 (P = 0.60), P = 0.57) ISLTH C: Events 2 0 1 if = 2 (P = 0 4 (P = 0.85) 0 5 0 2 1 (P = 0.46), 1 = 0.88) 1/2 antirejec	P = 0% AV III 0 9 2 13 0.52); P = 0 (CE-I/ARB: To P = 0%	21 86 No ISLTH Events 0 8 4 4 16 0% s No bao s No bao 17 0 17 0 17 28 apy 3/4	0 11 CAV III Total 0 31 11 20 62 Exervits 0 5 0 3 8 antirejecti	Weigh 60.09 7.89 100.09 ACE-I/AR 10 0.09	1 6. 35 100 00 10 10 10 10	10% 1 10,0%	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] 0.78 [0.33, 1.85] 0.78 [0.33, 1.85] 0.78 [0.33, 1.85] 1.50 [0.14, 4.80] 1.4, 4.80] 0.14, 4.80] 0.11, 86.33 0.01 0.0	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 959 0.01 0.1 ACE-I/ARBs better ACE- Odds Ratio	10 10 10 10 10 10 10 10 10 1 10 1 10 1 10 1
Total (95% CI) Total events Heterogeneity: Chi ^a = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ^a = 1.33, c Test for overall effect Z = 0.1 Battion et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ^a = 0.54, df = 1 Test for overall effect Z = 0.15 (P	5 22 3 (P = 0.60); P = 0.57) ISLTH C: Events 0 2 0 1 3 of = 2 (P = 0 0 1 0 2 0 1 1 of = 2 (P = 0.60; 1 0 2 0 1 1 0 2 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	P = 0% AV III <u>Total</u> 0 9 2 2 13 0.52); P = 10 10 10 10 10 10 10 10 10 10	21 86 No ISLTH Events 0 8 4 4 16 0 5 No bac tal 0 17 0 17 0 11 28 appy 3/4 Total	0 11 CAV III Total 0 31 11 20 62 ckground / Events 0 5 0 3 8 antirejecti Events	Weigh 60.09 7.89 100.09 ACE-I/AR 10 0.09	1 6. 35 100 t M-H, 5 0. 5 0. 5 0. 5 0. 11 4 34 10 11 4 34 10 10 11 8 11 4 34 10 10 11 8 11 9 10 10 10 10 10 10 10 10 10 10	10% 1 10,0%	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio .95% CI timable (4, 4.80] 01, 8.63] 0, 78.79] 44, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% C 1.09 [0.34, 3.48] Odds Ratio M.H, Fixed, 95%	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH CAV III better Odds Ratio M.H, Fixed, 959 0.01 0.1 ACE-WARBs better ACE- Odds Ratio	10 11 10 11 AV III worse 4 CI
Total (95% CI) Total events Heterogeneity: Chi ² = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 1.33, c Test for overall effect Z = 0.1 Study or Subgroup Bottio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 0.54, df = 1 Test for overall effect Z = 0.15 (P Study or Subgroup Bottio et al.,	5 22 3 (P = 0.60); P = 0.57) ISLTH C: Events 0 2 0 1 1 2 0 1 3 3 2 0 1 4 (P = 0.88) 0 5 0 2 0 1 1 (P = 0.46); 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 1 2 0 1 2 0 1 2 0 1 2 1 2 2 0 1 1 2 2 1 2 1 2 1 2 1 2 1 2 1 2 2 1 2 1 2 2 1 1 2 2 1 2 1 2 2 1 2 2 1 2 2 1 2 1 2 2 1 2 2 1 2 2 1 2 2 2 1 2 2 1 2 2 1 2 2 1 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 1 2 1 2 1 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	P = 0% AV III 0 9 2 2 13 0.52); P = 10 CCE-I/ARB: To P = 0% CCE-I/ARB: 10 10 10 10 10 10 10 10 10 10	21 86 No ISLTH Events 0 8 4 4 16 0% 8 No bac tal 0 17 0 11 28 apy 3/4 18	0 11 CAV III Total 0 31 11 20 62 Events 0 5 0 3 8 antirejecti <u>Events</u> 0	Weigh 60.09 7.89 100.09 ACE-I/AR 10 0.09	1 6. 35 100 t M-H, 6 0. 6 0. 6 0. 6 0. 10 0. 11 4 34 10 11 4 34 10 10 0 11 8 11 4 10 0 11 4 10 0 10 0 10 10 0 10 0 10 10	.0% 1 .0% 1 .0% .0% .0% .0% .00 .00 .00 .00 .00 .00	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] atio .95% CI timable [4, 4.80] 1, 8.63] 0, 78.79] 24, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% 1.09 [0.34, 3.48] Odds Ratio M.H, Fixed, 95% 11.09 [0.55, 221.3]	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95% Odds Ratio ACE-VARBs better ACE- Odds Ratio	10 11 10 11 AV III worse 4 CI
Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.86, df =: Test for overall effect $Z = 0.57$ (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.33, d Test for overall effect $Z = 0.1$ Batto et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ⁹ = 0.54, df = 1 Test for overall effect $Z = 0.15$ (P Study or Subgroup Bottio et al., French multicenter registry Bottio et al., French multicenter registry Bottio et al., French multicenter registry	5 22 3 (P = 0.60); P = 0.57) ISLTH CJ Events 0 2 0 1 1 2 0 1 1 2 0 1 2 0 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 0 1 1 2 2 (P = 0.88) 5 2 2 2 2 2 2 2 2 2 2 2 2 2	P = 0% AV III 0 9 2 13 0.52); P = 0 (CE-I/ARB: To P = 0%	21 86 No ISLTH Events 0 8 4 4 4 16 0% s No bac tal 0 17 0 17 0 11 28 apy 3/4 5	0 11 CAV III Total 0 31 11 20 62 5 0 5 0 3 8 antirejecti Events 0 9	Weigh 60.09 7.89 100.09 ACE-I/AR 10 0.09	1 6. 35 100 t M-H, 5 0. 5	.0% 1 .0% 1 .0% .0% .0% .0% .00 .00 .00 .00 .00 .00	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] 1.078 [0.33, 1.85] 1.95% CI timable 4, 4.80] 1.863] 1.863] 1.863] 1.863] 0.01 Odds Ratio M-H, Fixed, 95% C Not estimable 0.59 [0.08, 4 50] 1.09 [0.34, 3.48] Odds Ratio M-H, Fixed, 95% 11.09 [0.52, 221.5] 0.72 (0.07, 7.3]	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95% 0.01 0.1 ACE-WARBs better ACE- Odds Ratik CI M.H, Fixed, 95	10 11 10 11 AV III worse 4 CI
Total (95% CI) Total events Heterogeneity: Chi ² = 1.86, df =: Test for overall effect $Z = 0.57$ (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 1.33, d Test for overall effect $Z = 0.1$ Battio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 0.54, df = 1 Test for overall effect $Z = 0.15$ (P Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Study or Subgroup	5 22 3 (P = 0.60); P = 0.57) ISLTH C: Events 0 2 0 1 if = 2 (P = 0 4 (P = 0.85) ackground A Events 0 5 0 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	P = 0% AV III 0 9 2 13 0.52); P = 0 (CE-I/ARB: To P = 0%	21 86 No ISL TH Events 0 8 4 4 16 0% 8 No bao 16 0% 8 No bao 17 0 17 0 17 0 11 128 8 4 4 4 4 4 5 0 0 0 16 0 17 0 0 10 11 128 18 10 10 10 10 10 10 10 10 10 10	0 11 Total 0 31 11 20 62 ckground / Events 0 5 0 3 8 antirejecti Events 0 9 0	Weigh 60.09 7.89 100.09 ACE-I/AR 10 0.09	1 6. 35 100 0 10 10 10 10 10 10 11 10 10	i.0% 1 i.0% 1 i.0% 1 i.1%red. Not es 8.2 [0,1] 33 [0,0] 1.33 [0,0] 10 [0,2] 991 [0,2] 10.2 Veight 10.0% 45.0% 00.0% Veight 18.6% 81.4% 1.4%	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] 1.078 [0.33, 1.85] 1.078 [0.33, 1.85] 1.078 [0.33, 1.85] 1.078 [0.33, 1.85] 1.08 [0.18 [0.10] 0.01	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95% Odds Ratio M.H, Fixed, 95% Odds Ratio M.H, Fixed, 95% Odds Ratio	10 10 10 10 10 10 10 10 10 1 10 1 10 1 10 1
Total (95% CI) Total events Heterogeneity: Chi ² = 1.86, df =: Test for overall effect $Z = 0.57$ (f Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 1.33, d Test for overall effect $Z = 0.1$ Battio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ² = 0.54, df = 1 Total (95% CI) Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total events Heterogeneity: Chi ² = 0.54, df = 1 Test for overall effect $Z = 0.15$ (P	5 22 3 (P = 0.60); P = 0.57) ISLTH C: Events 0 2 0 1 if = 2 (P = 0 4 (P = 0.85) ackground A Events 0 5 0 2 1 (P = 0.46); (P = 0.46); 1 (P = 0% AV III 0 9 2 2 13 0.52); P = 13 0.52); P = 10 CE-I/ARB: To P = 0% ction there	21 86 No ISL TH Events 0 8 4 4 16 0 5 0 17 0 17 0 17 0 17 28 appy 3/4 Total 18 5 0	0 11 Total 0 31 11 20 62 ckground / Events 0 5 0 3 8 antirejecti Events 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0	Weigh 60.09 7.89 100.09 ACE-I/AR 10 0.09	1 6. 35 100 0 10 10 10 10 10 10 11 10 10	.0% 1 .0% 1 .0% .0% .0% .0% .00 .00 .00 .00 .00 .00	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] 0.78 [0.33, 1.85] 0.78 [0.33, 1.85] 0.78 [0.33, 1.85] 0.95% CI timable 4, 4.80] 01, 8.63] 0, 78.79] 4, 3.42] 0.01 Odds Ratio M.H, Fixed, 95% C 1.09 [0.36, 8.32 Not estimable 0.59 [0.08, 4.50 1.09 [0.34, 3.48] Odds Ratio M.H, Fixed, 95% 1.09 [0.55, 22.1] 0.72 [0.07, 7.3] Not estimation 0.72 [0.07, 7.3] Not estimation 0.72 [0.07, 7.3] Not estimation 0.72 [0.07, 7.3] 0.72 [0.07,	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95% Odds Ratio M.H, Fixed, 95% Odds Ratio M.H, Fixed, 95% Odds Ratio	10 11 10 11 AV III worse 4 CI
Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.86, df =: Test for overall effect Z = 0.57 (d Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ⁹ = 1.33, d Test for overall effect Z = 0.1 Batto et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., Total (95% CI) Total events Heterogeneity: Chi ⁹ = 0.54, df = 1 Test for overall effect Z = 0.15 (P Study or Subgroup Bottio et al., French multicenter registry Garcia-Cosio et al., French multicenter registry Garcia-Cosio et al., Singhvi et al., French multicenter registry Garcia-Cosio et al., Singhvi et al.,	5 22 3 (P = 0.60); P = 0.57) ISLTH CI Events 0 2 0 1 3 ackground A Events 0 5 0 2 0 1 1 2 0 1 2 0 1 1 2 0 1 2 0 1 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 2 0 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	P = 0% AV III 0 9 2 2 13 0.52); P = 0.52); P = 0%	21 86 No ISLTH Events 0 8 4 4 16 0 5 No bas tal 0 17 0 11 28 apy 3/4 Total 18 5 0 0 23	0 11 Total 0 31 11 20 62 ckground / Events 0 5 0 3 8 antirejecti Events 0 9 0	Weigh 60.09 7.89 100.09 ACE-I/AR 10 0.09	1 6. 35 100 0 10 10 10 10 10 10 11 10 10	i.0% 1 i.0% 1 i.0% 1 i.1%red. Not es 8.2 [0,1] 33 [0,0] 3.3 [0,0] 10 [0,2] 9.9 [0,2] 9.1 [0,2] Veight 18.6% 81.4% 1.4%	1.00 [0.04, 28.30] 0.78 [0.33, 1.85] 1.078 [0.33, 1.85] 1.078 [0.33, 1.85] 1.078 [0.33, 1.85] 1.078 [0.33, 1.85] 1.08 [0.18 [0.10] 0.01	Hypertension better Hyper Odds Ratio M.H, Fixed, 95% CI 0.1 ISLTH CAV III better ISLTH C Odds Ratio M.H, Fixed, 95% Odds Ratio M.H, Fixed, 95% Odds Ratio M.H, Fixed, 95% Odds Ratio	10 11 10 11 AV III worse 4 CI

Figure 2 Demographics and comorbidities according to occurrence of death in heart transplant recipients with COVID-19. ACE-I, angiotensinconverting enzyme inhibitors; ARB, angiotensin receptor blockers; CAV, cardiac allograft vasculopathy; CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; DM, diabetes mellitus; ISHLT, International Society for Heart and Lung Transplantation; M-H, Mantel-Haenszel. For the impact of CKD and number of background immunosuppressive therapy, data presented for Bottio *et al.* [52], are from the study by lacovoni *et al.* [17], which were eventually included in the study of Bottio *et al.* CoV-2 infection in HT recipients remains to be established. Management of immunosuppressive medications as well as administration of antiviral therapies was left at the discretion of transplant teams according to local practices, thus preventing the drawing of any conclusion. Only routine laboratory tests were performed in patients precluding any detailed evaluation of the inflammatory response to COVID-19 in HT recipients. Furthermore, the comparison of the overall mortality among HT recipients in our three centres between the period of interest and the previous year should be cautiously interpreted considering the small number of confirmed COVID-19 cases. Nonetheless, we believe that our findings could serve as incentive for larger studies with extended period of interest. Finally, a publication bias may have skewed our systematic review as well as meta-analysis results. Indeed, while studies reporting on mortality could have been more easily published, reported results were from small observational studies with short-term follow-up. In addition, only available data authors considered interesting were included in the analyses.

In conclusion, this multicentre case series shows that the clinical course of COVID-19 is aggressive in HT recipients even after reduction of immunosuppressive. Increased inflammation and lung involvement extent at admission in addition to pre-existing diabetes and chronic kidney disease are associated with risk of death.

Conflicts of interest

The authors have no disclosure regarding the present studies.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. STROBE statement—checklist.

Table S2. Practical guide from the French Society of Transplantation for immunosuppressive therapy management in heart transplant recipient with COVID-19.

Table S3. PRISMA—checklist.

Table S4. Systematic review of studies reporting outcomes among heart transplant recipients affected by COVID-19.

Figure S1. Multiple polymerase chain reaction test results from nasopharyngeal swabs.

Figure S2. Flow chart of studies selection for the meta-analysis.

Figure S3. Funnel plot analysis for diabetes mellitus (a), chronic kidney disease stage III or higher (b), hypertension (c), male gender (d), background use of ACE-I/ARBs (e), number of background immunosuppressive therapies (f), and cardiac allograft vasculopathy (g).

Funding

The authors have declared no funding.

REFERENCES

- 1. COVID-19 Map [Internet]. Johns Hopkins Coronavirus Resource Center. [Cité 4 Nov 2020.] Disponible sur: https://coronavirus.jhu.edu/map.html.
- Zhou P, Yang X-L, Wang X-G, *et al*. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; 579: 270.
- Fried JA, Ramasubbu K, Bhatt R, *et al.* The variety of cardiovascular presentations of COVID-19. *Circulation* 2020; 141: 1930.
- Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323: 2052.

- 5. Zendjebil S, Zeitouni M, Batonga M, et al. Acute multivessel coronary occlusion revealing COVID-19 in a young adult. JACC Case Rep 2020; 2: 1297.
- López-Medrano F, Aguado JM, Lizasoain M, *et al.* Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. *Transplantation* 2007; 84: 851.
- van de Beek D, Kremers WK, Del Pozo JL, *et al.* Effect of infectious diseases on outcome after heart transplant. *Mayo Clin Proc* 2008; 83: 304.
- 8. Pons S, Sonneville R, Bouadma L, et al. Infectious complications following heart transplantation in the era of high-priority allocation and

extracorporeal membrane oxygenation. Ann Intensive Care 2019; 9: 17.

- 9. Holzhauser L, Lourenco L, Sarswat N, Kim G, Chung B, Nguyen AB. Early experience of COVID-19 in 2 heart transplant recipients: case reports and review of treatment options. *Am J Transplant* 2020; **20**: 2916.
- Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant 2020; 20: 1849.
- 11. Fung M, Chiu CY, DeVoe C, et al. Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: a case series

from the United States. Am J Transplant 2020; 20: 3225.

- Mathies D, Rauschning D, Wagner U, et al. A case of SARS-CoV-2 pneumonia with successful antiviral therapy in a 77-year-old man with a heart transplant. Am J Transplant 2020; 20: 1925.
- Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation 2020; 141: 1648.
- Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr 2020; 14: 247.
- Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5: 811.
- 16. Latif F, Farr MA, Clerkin KJ, *et al.* Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019. *JAMA Cardiol* 2020: e202159.
- Iacovoni A, Boffini M, Pidello S, et al. A case series of novel coronavirus infection in heart transplantation from 2 centers in the pandemic area in the North of Italy. J Heart Lung Transplant 2020; 39: 1081.
- Singhvi A, Barghash M, Lala A, et al. Challenges in heart transplantation during COVID-19: a single center experience. J Heart Lung Transplant 2020; 39: 894.
- Ketcham SW, Adie SK, Malliett A, et al. Coronavirus disease-2019 in heart transplant recipients in Southeastern Michigan: a case series. J Card Fail 2020; 26: 457.
- Bösch F, Börner N, Kemmner S, et al. Attenuated early inflammatory response in solid organ recipients with COVID-19. Clin Transplant 2020: 34: e14027.
- Tschopp J, L'Huillier AG, Mombelli M, et al. First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. Am J Transplant 2020; 20: 2876.
- Hoek RAS, Manintveld OC, Betjes MGH, et al. COVID-19 in solid organ transplant recipients: a single-center experience. Transpl Int 2020; 33: 1099.
- 23. Yi SG, Rogers AW, Saharia A, et al. Early experience with COVID-19 and solid organ transplantation at a US high-volume transplant center. Transplantation 2020; 104: 2208.
- Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant 2020; 39: 496.
- Hsu JJ, Gaynor P, Kamath M, et al. COVID-19 in a high-risk dual heart and kidney transplant recipient. Am J Transplant 2020; 20: 1911.

- 26. Kates OS, Fisher CE, Stankiewicz-Karita HC, et al. Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States. Am J Transplant 2020; 20: 1885.
- Lima B, Gibson GT, Vullaganti S, et al. COVID-19 in recent heart transplant recipients: clinicopathologic features and early outcomes. *Transpl Infect Dis* 2020; 22: e13382.
- Vaidya G, Czer LSC, Kobashigawa J, et al. Successful treatment of severe COVID-19 pneumonia with clazakizumab in a heart transplant recipient: a case report. *Transplant Proc* 2020; 52: 2711.
- 29. Mattioli M, Fustini E, Gennarini S. Heart transplant recipient patient with COVID-19 treated with tocilizumab. *Transpl Infect Dis* 2020; **22**: e13380.
- Jang K, Khatri A, Majure DT. COVID-19 leading to acute encephalopathy in a patient with heart transplant. J Heart Lung Transplant 2020; 39: 853.
- Kadosh BS, Pavone J, Wu M, Reyentovich A, Gidea C. Collapsing glomerulopathy associated with COVID-19 infection in a heart transplant recipient. J Heart Lung Transplant 2020; 39: 855.
- 32. Stachel MW, Gidea CG, Reyentovich A, Mehta SA, Moazami N. COVID-19 pneumonia in a dual heart-kidney recipient. *J Heart Lung Transplant* 2020; **39**: 612.
- 33. Decker A, Welzel M, Laubner K, et al. Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation. Am J Transplant 2020; 20: 3239.
- 34. Serrano OK, Kutzler HL, Rochon C, et al. Incidental COVID-19 in a heartkidney transplant recipient with malnutrition and recurrent infections: Implications for the SARS-CoV-2 immune response. *Transpl Infect Dis* 2020; **22**: e13367.
- 35. Ahluwalia M, Givertz MM, Mehra MR. A proposed strategy for management of immunosuppression in heart transplant patients with COVID-19. *Clin Transplant* 2020; **34**: e14032.
- 36. Soquet J, Rousse N, Moussa M, et al. Heart retransplantation following COVID-19 illness in a heart transplant recipient. J Heart Lung Transplant 2020; 39: 983.
- Felldin M, Søfteland JM, Magnusson J, et al. Initial report from a Swedish high-volume transplant center after the first wave of the COVID-19 pandemic. *Transplantation* 2021; 105: 108.
- Rivinius R, Kaya Z, Schramm R, et al. COVID-19 among heart transplant recipients in Germany: a multicenter

survey. Clin Res Cardiol 2020; 109: 1531.

- 39. Ammirati E, Travi G, Orcese C, *et al.* Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy. *Int J Cardiol Heart Vasc* 2020; **29**: 100596.
- Vilaro J, Al-Ani M, Manjarres DG, et al. Severe COVID-19 after recent heart transplantation complicated by allograft dysfunction [Internet]. JACC Case Rep 2020; 2: 1347.
- Sperry BW, Khumri TM, Kao AC. Donor-derived cell free DNA in a heart transplant patient with COVID-19. *Clin Transplant* 2020; 34: e14070.
- 42. Ravanan R, Callaghan CJ, Mumford L, et al. SARS-CoV-2 infection and early mortality of wait-listed and solid organ transplant recipients in England: a national cohort study. Am J Transplant 2020; 20: 3008.
- 43. Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis 2020. [Internet]. [Cité 12 sept 2020.] Disponible sur: https:// academic.oup.com/cid/advance-article/ doi/10.1093/cid/ciaa1097/5885162.
- 44. Caraffa R, Bagozzi L, Fiocco A, et al. Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience. Eur J Cardiothorac Surg 2020; **58**: 899.
- 45. Mastroianni F, Leisman DE, Fisler G, Narasimhan M. General and intensive care outcomes for hospitalized patients with solid organ transplants with COVID-19. *J Intensive Care Med* 2020 [cité 5 Nov 2020]; Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC7548542/.
- Schtruk LE, Miranda J, Salles V, et al. COVID-19 infection in heart transplantation: case reports. Arq Bras Cardiol 2020; 115: 574.
- 47. García-Cosío MD, Flores Hernán M, Caravaca Pérez P, López-Medrano F, Arribas F, Delgado Jiménez J. Heart transplantation during the coronavirus disease 2019 pandemic: follow-up organization and characteristics of infected patients. *Rev Esp Cardiol* 2020; 73: 1077.
- Al-Darzi W, Aurora L, Michaels A, et al. Heart transplant recipients with confirmed 2019 novel coronavirus infection: the Detroit experience. *Clin Transplant* 2020; 34: e14091.
- 49. Rahman F, Liu STH, Taimur S, *et al.* Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: experience at large transplant center in New York City. *Clin Transplant* 2020; **34**: e14089.

- 50. Sharma P, Chen V, Fung CM, *et al.* COVID-19 outcomes among solid organ transplant recipients: a case-control study. *Transplantation* 2021; **105**: 128.
- Fiocco A, Ponzoni M, Caraffa R, et al. Heart transplantation management in northern Italy during COVID-19 pandemic: single-centre experience. ESC Heart Fail 2020; 7: 2003.
- 52. Bottio T, Bagozzi L, Fiocco A, *et al.* COVID-19 in heart transplant recipients: a multicenter analysis of the Northern Italian outbreak. *JACC Heart Fail* 2020; **9**: 52.
- Coll E, Fernández-Ruiz M, Sánchez-Á lvarez JE, *et al.* COVID-19 in transplant recipients: the Spanish experience. *Am J Transplant* 2020; 1 (ahead of print).
- Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708.
- 55. Manuel O, Estabrook M, American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid

organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* 2019; **33**: e13511.

- 56. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis. *Trop Med Infect Dis* 2020; **5**: 80.
- 57. Kumar A, Arora A, Sharma P, *et al.* Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes Metab Syndr* 2020; **14**: 535.
- Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int* 2020; 97: 829.
- 59. Wang X, Fang X, Cai Z, *et al.* Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis. *Research* 2020; **2020**: 2402961.
- 60. Hoffmann M, Kleine-Weber H, Schroeder S, *et al.* SARS-CoV-2 cell

entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020; **181**: 271.e8.

- Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605.
- Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med 2020; 382: 2441.
- Rodriguez-Cubillo B, de la Higuera MAM, Lucena R, *et al.* Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? *Am J Transplant* 2020; 20: 3173.
- 64. RECOVERY Collaborative Group, Horby P, Lim WS, et al.Dexamethasone in hospitalized patients with Covid-19 – preliminary report. N Engl J Med 2020. [Cité 12 sept 2020]; Disponible sur: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC7383595/.